📊 QURE Key Takeaways
Is uniQure N.V. (QURE) a Good Investment?
uniQure faces severe financial distress with -$178.4M free cash flow burn, collapsing revenue (-40.6% YoY), and unsustainable operating losses of -$199M. At the current burn rate, the company's $80.2M cash position provides less than 6 months of runway, necessitating imminent capital raises that will cause significant shareholder dilution.
Why Buy uniQure N.V. Stock? QURE Key Strengths
- Strong current ratio of 10.43x provides adequate short-term liquidity buffer
- Moderate debt-to-equity ratio of 0.36x indicates capacity for additional financing
- Maintains $80.2M cash reserves for near-term operations
QURE Stock Risks: uniQure N.V. Investment Risks
- Catastrophic cash burn of -$178.4M annually with limited runway before insolvency
- Revenue collapsing at -40.6% YoY indicates failed commercialization or market rejection of products
- Operating losses of -$199M with -1236% net margin show no path to profitability without major business restructuring
- Imminent dilutive capital raise required to survive, destroying shareholder value
- Negative ROE of -100% and ROA of -24.1% demonstrate value destruction across all metrics
Key Metrics to Watch
- Quarterly operating cash flow trend and absolute burn rate deceleration
- Revenue per product and product-by-product adoption metrics
- Cash position runway and any capital raise announcements
- Pipeline advancement, regulatory approvals, and commercial launch timelines
- Cash burn rate sustainability relative to remaining capital
uniQure N.V. (QURE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.43x current ratio provides a solid financial cushion.
QURE Profit Margin, ROE & Profitability Analysis
QURE vs Healthcare Sector: How uniQure N.V. Compares
How uniQure N.V. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is uniQure N.V. Stock Overvalued? QURE Valuation Analysis 2026
Based on fundamental analysis, uniQure N.V. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
uniQure N.V. Balance Sheet: QURE Debt, Cash & Liquidity
QURE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: uniQure N.V.'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-6.47 indicates the company is currently unprofitable.
QURE Revenue Growth, EPS Growth & YoY Performance
QURE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.3M | -$44.4M | $-0.91 |
| Q2 2025 | $5.3M | -$37.7M | $-0.69 |
| Q1 2025 | $1.6M | N/A | $-0.82 |
| Q3 2024 | $1.4M | N/A | $-0.91 |
| Q2 2024 | $2.4M | N/A | $-1.16 |
| Q1 2024 | $5.3M | N/A | $-1.36 |
| Q3 2023 | $1.4M | N/A | $-1.02 |
| Q2 2023 | $497.0K | N/A | $-0.84 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
uniQure N.V. Dividends, Buybacks & Capital Allocation
QURE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for uniQure N.V. (CIK: 0001590560)
📋 Recent SEC Filings
❓ Frequently Asked Questions about QURE
What is the AI rating for QURE?
uniQure N.V. (QURE) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are QURE's key strengths?
Claude: Strong current ratio of 10.43x provides adequate short-term liquidity buffer. Moderate debt-to-equity ratio of 0.36x indicates capacity for additional financing.
What are the risks of investing in QURE?
Claude: Catastrophic cash burn of -$178.4M annually with limited runway before insolvency. Revenue collapsing at -40.6% YoY indicates failed commercialization or market rejection of products.
What is QURE's revenue and growth?
uniQure N.V. reported revenue of $16.1M.
Does QURE pay dividends?
uniQure N.V. does not currently pay dividends.
Where can I find QURE SEC filings?
Official SEC filings for uniQure N.V. (CIK: 0001590560) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is QURE's EPS?
uniQure N.V. has a diluted EPS of $-3.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is QURE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, uniQure N.V. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is QURE stock overvalued or undervalued?
Valuation metrics for QURE: ROE of -100.0% (sector avg: 15%), net margin of -1,236.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy QURE stock in 2026?
Our dual AI analysis gives uniQure N.V. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is QURE's free cash flow?
uniQure N.V.'s operating cash flow is $-178.0M, with capital expenditures of $439.0K. FCF margin is -1,108.2%.
How does QURE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,236.0% (avg: 12%), ROE -100.0% (avg: 15%), current ratio 10.43 (avg: 2).